Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for neurological, psychiatric, endocrine, and immunological disorders in the United States and international markets. Its approved products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease, Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia. The company also markets ALKINDI and Efmody. In addition to its commercial portfolio, Neurocrine Biosciences has a pipeline of product candidates in clinical development across movement disorders, major depressive disorder, schizophrenia, bipolar mania, Alzheimer’s disease, epilepsy, congenital adrenal hyperplasia, obesity and related metabolic diseases, and other neuropsychiatric and neurological conditions. The company was incorporated in 1992 and is headquartered in San Diego, California. Its common stock is listed on the NASDAQ exchange under the symbol NBIX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NBIX
|
$213.65
|
20.5% Upside
|
Undervalued
|
$200.24
|
13.0% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
26.7x
|
5.2x
|
5.7x
|
17.395 B
|
15.509 B
|
2.6%
|
98.8%
|
8.7
|
—
|
124.3%
|
